My point is that if Serca2 was found in biopsyes of the higher dose individuals and non in the placebo group, so the vector works
Are you as certain as you were that I was mixing up AAV1 and AAV2?
I think this contention is weak, because:
1) They did not detect SERCA2 but rather detected the presence of a sequence specific to the recombinant virus they injected. 2) Yes, the did detect more virus in *some* (not all!) individuals in the higher dose group than they did in the placebo group... but it would have been a miracle to detect any recombinant AAV in the placebo group.
Honestly, I have no intention of getting in between you and your investment. This is simply an area where I did plenty of hands-on work, and figured I could contribute a point or two.
AI
